Who holds nusinersen’s patents, and what are they protecting?
Nusinersen is a drug sold as Spinraza for spinal muscular atrophy. Patent coverage around nusinersen generally protects key parts of the invention—such as the specific oligonucleotide design, chemical modifications, and related manufacturing and use claims—rather than only the brand name. Public patent and legal coverage is typically split across multiple jurisdictions and can change over time as different families expire and others remain active.
When do nusinersen patents expire?
Patent expiry depends on (1) the specific patent family, (2) the country or region, and (3) whether any patent-term extensions or supplemental protections apply. For nusinersen, there is no single “one date” that covers every claim in every market; different patents within the same overall technology portfolio expire in different years across different geographies.
Can a generic or biosimilar nusinersen enter before patent expiry?
Full generic competition is generally unlikely while core patents covering the active ingredient and its critical features remain in force. Even if some patents expire earlier, later-expiring patents (for example, around specific molecular characteristics or methods of use) can still block market entry in certain countries. For nusinersen specifically, the entry path for competitors typically depends on which claims are still enforceable and whether a challenge (or “launch at risk”) succeeds.
Are other companies trying to challenge nusinersen patents?
Patent challenges can occur through litigation or administrative proceedings, but the outcomes are jurisdiction-specific and depend on the particular patent claims being asserted. Whether a challenge affects market entry hinges on what courts decide about validity and infringement for each asserted patent.
What patents matter most for market competition?
The practical patents that usually matter for competition are the ones that:
protect the exact oligonucleotide design (including modifications),
cover manufacturing or quality-related aspects,
or claim specific clinical use(s) or dosing approaches that competitors would need to match to be allowed to market an alternative.
How to check nusinersen patent status in a specific country
To answer “is it still patented?” for nusinersen, you typically need:
the target country,
the relevant patent family numbers (or application/publication identifiers),
and the regulatory status for that market (including any patent-term extensions).
Patent databases (and national “regulatory exclusivity” registries) are the usual starting points, because expiry can differ even when patents share the same priority date.
Why patent dates can look confusing for nusinersen
Different document types can create apparent contradictions:
A single priority date can lead to many later filings.
Some patents expire earlier due to maintenance/term rules, while others remain active.
Adjustments/extensions can shift effective expiry in certain regions.
What you can do if you need the exact expiry date for nusinersen
If you tell me the country/region you care about (for example, US, EU, UK, Canada, Japan, or China), I can narrow the answer to the relevant market-specific expiry questions—because “nusinersen patent expiry” is inherently location- and claim-dependent.
Sources
No sources were provided in the prompt, so I can’t cite specific nusinersen patent documents or exact expiry dates yet.